Table 1.
FOLFCIS n=53 |
Other regimens n=34 |
|
---|---|---|
Age (years) Median Range |
59 39–78 |
60 32–83 |
Sex (%) Male Female |
22 (42) 31 (58) |
17 (50) 17 (50) |
Immunosuppression (%) HIV infection Solid Organ transplant Anti-TNF therapy |
5 (9) 0 3 (6) |
5 (15) 2 (6) 0 (0) |
ECOG (%) 0 1 2 Unknown |
29 (55) 22 (41) 2 (4) 0 |
15 (44) 14 (41) 3 (9) 2 (6) |
Stage at diagnosis (%) Stage I Stage II Stage III Stage IV |
3 (6) 15 (28) 18 (34) 17 (32) |
2 (6) 8 (24) 15 (44) 9 (26) |
Extent of disease (%) Metastatic Locally advanced |
48 (91) 5 (9) |
31 (91) 3 (9) |
Histology (%) Squamous: NOS Squamous: Basaloid |
43 (81) 10 (19) |
26 (76) 8 (24) |
Tumor differentiation (%) Well Moderate Poor |
3 (6) 23 (43) 27 (51) |
4 (12) 14 (41) 16 (47) |
HPV status (%) Positive Negative |
n=34 29 (85) 5 (15) |
n=14 13 (93) 1 (7) |
First sites of metastasis Liver Lung Bone Peritoneum Other |
27 (51) 14 (26) 1 (2) 2 (4) 2 (4) |
17 (50) 5 (15) 5 (15) 1 (3) 5 (15) |
Abbreviation: HPV, Human papillomavirus; NOS, Not otherwise specified.